ArticleThoracic cancer2022

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.

Yuji Uehara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.